Chronic myelogenous leukemia: Clinical practice guidelines in oncology

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 3, Issue 6, 2005, Pages 732-755

  O'Brien, Susan ^a   Berman, Ellin ^b   Bhalla, Kapil ^c   Copelan, Edward A ^d   Devetten, Marcel P ^e   Emanuel, Peter D ^f   Erba, Harry P ^g   Greenberg, Peter L ^h   Moore, Joseph O ⁱ   Przepiorka, Donna ^j   Radich, Jerald P ^k   Schilder, Russell J ^l   Shami, Paul ^m   Smith, B Douglas ⁿ   Snyder, David S ^o   Soiffer, Robert J ^p   Tallman, Martin S ^q   Talpaz, Moshe ^a   Wetzler, Meir ^r  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e NEBRASKA MEDICAL CENTER   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^h STANFORD UNIVERSITY MEDICAL CENTER   (United States)

ⁱ DUKE CANCER INSTITUTE   (United States)

^j UNIVERSITY OF TENNESSEE CANCER INSTITUTE   (United States)

^k SEATTLE CANCER CARE ALLIANCE   (United States)

^l FOX CHASE CANCER CENTER   (United States)

^m UNIVERSITY OF UTAH   (United States)

ⁿ JOHNS HOPKINS UNIVERSITY   (United States)

^o City of Hope Cancer Center   (United States)

^p Dana Farber/Partners CancerCare   (United States)

^q NORTHWESTERN UNIVERSITY   (United States)

^r ROSWELL PARK CANCER INSTITUTE   (United States)

more..

Author keywords

Acute lymphocytic leukemia; Allogeneic transplantation; Chronic myelogenous leukemia; Cytarabine; Hematopoietic stem cell transplant; Imatinib mesylate; Interferon; NCCN Clinical Practice Guidelines

Indexed keywords

ANAGRELIDE; CALCIUM; CYTARABINE; DIURETIC AGENT; ERYTHROPOIETIN; FIBRINOLYTIC AGENT; GROWTH FACTOR; HYDROXYUREA; IMATINIB; INTERFERON; PARACETAMOL; STEROID; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; HYBRID PROTEIN; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANEMIA; APHERESIS; BLAST CELL CRISIS; BONE MARROW EXAMINATION; BONE MARROW TRANSPLANTATION; CANCER RELAPSE; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; CLINICAL TRIAL; CYTOPENIA; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG WITHDRAWAL; EDEMA; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKOCYTOSIS; LIVER TOXICITY; MUSCLE CRAMP; NEUTROPENIA; ONSET AGE; PRACTICE GUIDELINE; RASH; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOCYTOSIS; ALGORITHM; ALLOTRANSPLANTATION; ARTICLE; CELL TRANSFORMATION; CHEMISTRY; CHROMOSOME 22; CHROMOSOME 9; CHROMOSOME ANALYSIS; CHROMOSOME BREAKAGE; CYTOLOGY; DRUG INTERACTION; GENE FUSION; GENE TRANSLOCATION; GENETICS; HEMATOPOIETIC STEM CELL; KARYOTYPING; METABOLISM; PATHOLOGY; RECURRENT DISEASE; REMISSION; STANDARD;

ALGORITHMS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME BREAKAGE; CHROMOSOMES, HUMAN, PAIR 22; CHROMOSOMES, HUMAN, PAIR 9; CYTARABINE; CYTOGENETIC ANALYSIS; DISEASE PROGRESSION; DRUG INTERACTIONS; GENE FUSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; INTERFERONS; KARYOTYPING; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PRACTICE GUIDELINES; PYRIMIDINES; RECOMBINANT FUSION PROTEINS; RECURRENCE; REMISSION INDUCTION; TRANSLOCATION, GENETIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 33644832711     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2005.0044     Document Type: Review

References (56)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Faderl S, Talpaz M, Estrov Z, et al. Chronic myelogenous leukemia: Biology and therapy. Ann Intern Med 1999;131:207-219.
3. Sawyers C. Chronic myeloid leukemia. N Engl J Med 1999;340:1330-1340.
4. Faderl SA, Talpaz M, Estrov Z, et al. The biology of chronic myeloid leukemia. N Engl J Med 1999;341:164-172.
5. Guo JQ, Wang JYG, Arlinghaus RB. Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients. Cancer Res 1991;51:3048-3051.
6. Muhlmann J, Thaler J, Hilbe W, et al. Fluorescent in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: a new strategy for remission assessment. Genes Chromosomes Cancer 1998;21:90-100.
7. Cortes J, Talpaz M, Beran M, et al. Philadelphia chromosome negative chronic myelogenous leukemia rearrangement of the breakpoint cluster region: long-term follow-up results. Cancer 1995;75:464-470.
8. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:940-1004.
9. le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000;95:1758-1766.
10. Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cells lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000;96:1070-1079.
11. Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000;95:3498-3505.
12. Zonder JA, Pemberton P, Brandt H, et al. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res 2003;9:2092-2097.
13. Kantarjian HM, Talpaz M, O'Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003;101:473-475.
14. Clift RA, Storb R. Marrow transplantation for CML: the Seattle experience. Bone Marrow Transplant 1996;17[suppl 3]:S1-S3.
15. Davies SM, DeFor TE, McGlave PB, et al. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am J Med 2001;110:339-346.
16. Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998;338:962-968.
17. Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: A report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1996;17[suppl 3]:S5-S6.
18. Goldman J, Szydlo R, Horowitz MM, et al. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 1993;82:2235-2238.
19. Beelen DW, Graeven U, Elmaagacli AH, et al. Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 1995;85:2981-2990.
20. Morton AJ, Gooley T, Hansen J A, et al. Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood 1998;92:394-401.
21. Hehlmann R, Hochhaus A, Kolb HJ, et al. Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. Blood 1999;94:3668-3677.
22. Giralt S, Szydlo R, Goldman JM, et al. Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: an analysis from the international bone marrow transplant registry. Blood 2000;95:410-415.
23. Clift RA, Radich J, Appelbaum FR, et al. Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during chronic phase of chronic myeloid leukemia. Blood 1999;94:3960-3962.
24. Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997;89:3055-3060.
25. Radich JP, Gooley T, Bensinger W, et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 2003;102:31-35.
26. Goldman JM, Gale RP, Horowitz MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988;108:806-814.
27. Elmaagacli AH, Beelen DW, Opalka B, et al. The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow. Blood 1999;94:384-389.
28. Radich JP, Gehly G, Gooley T, et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995;85:2632-2638.
29. Mackinnon S, Barnett L, Heller G. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 1996;17:643-647.
30. Radich JP, Gooley T, Bryant E et al. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation. Blood 2001;98:1701-1707.
31. Olavarria E, Kanfer E, Szydlo R, et al. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2001;97:1560-1565.
32. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995;86:2041-2050.
33. Higano CS, Chielens D, Raskind W, et al. Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation. Blood 1997;90:2549-2554.
34. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390-3400.
35. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997;89:4531-4536.
36. Giralt S, Thall P, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001;97:631-637.
37. Or R, Shapira M, Resnick I. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2003;101:441-445.
38. Druker BJ, Talpaz, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR/ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.
39. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-652.
40. Cortes J, Giles F, O'Brien S, et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood 2003;102:83-86.
41. Kantarjian HM, Cortes JE, O'Brien S, et al. Imatinib mesylate in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 2003;101:97-100.
42. Talpaz M, Silver R, Druker B, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99:1928-1937.
43. Kantarjian HM, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004;103:2873-2878.
44. Cortes, J, O'Brien S, Quintas A, et al. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer 2004;100:2396-2402.
45. Kantarjian H, Talpaz M, Cortes J, et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res 2003;9:160-166.
46. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423-1432.
47. Feldman E, Najfeld V, Schuster M et al. The emergence of Ph-, trisomy-8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Exp Hematol 2003;31:702-707.
48. Medina J, Kantarjian H, Talpaz M, et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 2003;98:1905-1911.
49. Bumm T, Muller C, Al-Ali HK, et al. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003;102:2700-2701.
50. O'Dwyer ME, Gatter KM, Loriaux M, et al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic meylogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 2003;17:481-487.
51. Kantarjian HM, O'Brien S, Smoith TL, et al. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon-alfa and low dose cytarabine. J Clin Oncol 1999;17:284-292.
52. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia: French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997;337:223-229.
53. Kantarjian HM, Deisseroth A, Kurzrock R, et al. Chronic myelogenous leukemia: a concise update. Blood 1993;82:691-703.
54. Savage DG, Szydlo RM, Chase A, et al. Bone marrow transplantation for chronic myeloid leukemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse. Br J Haematol 1997;99:30-35.
55. Sokal JE, Baccarani M, Russo D, et al. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 1988;25:49-61.
56. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.